Molecular Dynamics Simulations of Coronavirus Spike Protein-ACE2 Interactions: Implications for Host Range and Zoonotic Potential

Introduction

Coronaviruses represent a significant concern in veterinary medicine due to their capacity for cross-species transmission and emergence in novel hosts [1, 2]. The initial step of coronavirus entry into host cells is mediated by the viral spike glycoprotein, which engages the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface [3, 4]. The specificity and affinity of this interaction are primary determinants of host range and zoonotic potential [5, 6]. Molecular dynamics (MD) simulations have emerged as a powerful computational tool for dissecting the atomic-level details of spike protein-ACE2 interactions, providing quantitative predictions of binding free energies and conformational dynamics that govern species tropism [7, 8].

This article provides a comprehensive review of how MD simulations elucidate the biophysical principles underlying coronavirus spike protein-ACE2 recognition. The focus is on the implications for predicting cross-species transmission events in animal populations, with particular emphasis on the receptor-binding domain (RBD) of the spike protein and its conformational plasticity [9, 10]. The integration of MD simulations with other computational approaches, including virtual screening and free energy calculations, is discussed in the context of host range prediction [11, 12].

Structural Basis of Spike Protein-ACE2 Recognition

The coronavirus spike protein is a trimeric class I fusion glycoprotein that undergoes substantial conformational rearrangements during host cell entry [13, 14]. Each monomer comprises two functional subunits: the S1 subunit, which contains the RBD responsible for ACE2 recognition, and the S2 subunit, which mediates membrane fusion [15, 16]. The RBD adopts two principal conformations: a closed (down) state that is inaccessible for receptor binding and an open (up) state that exposes the receptor-binding motif (RBM) for ACE2 engagement [17, 18].

The ACE2 receptor is a type I transmembrane protein expressed on the surface of epithelial cells in multiple tissues, including the respiratory tract and gastrointestinal tract of various mammalian species [19, 20]. The interaction between the spike RBD and ACE2 involves a network of hydrogen bonds, hydrophobic contacts, and electrostatic interactions at the protein-protein interface [21, 22]. MD simulations have revealed that the binding interface is characterized by significant conformational flexibility, with key residues exhibiting dynamic fluctuations that modulate binding affinity [2, 5].

Molecular Dynamics Simulation Methodology

MD simulations solve Newton's equations of motion for a system of interacting atoms over time, generating trajectories that capture the conformational dynamics of biomolecules at atomic resolution [15, 16]. For spike protein-ACE2 systems, simulations are typically performed using all-atom force fields such as CHARMM or AMBER, with explicit solvent models to account for aqueous environment effects [17, 18]. The simulation protocol generally includes energy minimization, equilibration phases, and production runs spanning tens to hundreds of nanoseconds [19, 20].

The following table summarizes the key methodological components of MD simulations applied to spike protein-ACE2 systems:

Enhanced sampling techniques, including replica exchange molecular dynamics (REMD) and metadynamics, are frequently employed to overcome energy barriers and achieve more complete conformational sampling of the spike RBD [16, 17]. These methods are particularly valuable for studying the open-closed conformational transition of the RBD, which occurs on timescales that may be inaccessible to conventional MD simulations [18, 19].

Binding Free Energy Calculations

The binding free energy (ΔG_bind) between the spike RBD and ACE2 is a quantitative measure of interaction strength that correlates with viral infectivity and host range [1, 3]. MD simulations enable the calculation of binding free energies using several established methodologies:

1. Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA): This approach combines molecular mechanics energies with continuum solvation models to estimate binding free energies from MD trajectories [4, 6]. MM-PBSA calculations have been widely applied to compare the binding affinities of spike variants from different coronavirus species [7, 8].

2. Molecular Mechanics Generalized Born Surface Area (MM-GBSA): Similar to MM-PBSA but using the Generalized Born model for electrostatic solvation, this method offers computational efficiency suitable for screening multiple spike variants [9, 10].

3. Free Energy Perturbation (FEP): This rigorous alchemical approach calculates free energy differences between related states by gradually transforming one system into another [11, 12]. FEP simulations provide highly accurate relative binding free energies for point mutations in the spike RBD [13, 14].

4. Thermodynamic Integration (TI): An alternative alchemical method that computes free energy differences by integrating the derivative of the Hamiltonian with respect to a coupling parameter [15, 16].

The binding free energy values obtained from these methods have been correlated with experimental measurements of spike protein-ACE2 affinity, demonstrating the predictive power of MD-based approaches [17, 18]. For example, MM-PBSA calculations have shown that the binding affinity of spike RBD variants correlates with the efficiency of viral entry into cells expressing ACE2 from different species [19, 20].

Conformational Dynamics of the Receptor-Binding Domain

The RBD of the coronavirus spike protein exhibits pronounced conformational dynamics that are critical for receptor recognition and immune evasion [2, 5]. MD simulations have revealed that the RBD undergoes hinge-like motions that modulate the accessibility of the receptor-binding motif [6, 7]. The open conformation, which exposes the RBM for ACE2 binding, is stabilized by interactions between the RBD and the N-terminal domain of the spike protein [8, 9].

Principal component analysis (PCA) of MD trajectories has identified the dominant collective motions of the RBD, including twisting and bending modes that facilitate the open-closed transition [10, 11]. These motions are influenced by mutations in the RBD that alter the energy landscape of the conformational equilibrium [12, 13]. The following Mermaid diagram illustrates the workflow for analyzing RBD conformational dynamics using MD simulations:

flowchart TD
    A[Spike Protein Crystal Structure], > B[System Preparation]
    B, > C[Solvation and Ionization]
    C, > D[Energy Minimization]
    D, > E[Equilibration NVT/NPT]
    E, > F[Production MD Simulation]
    F, > G[Trajectory Analysis]
    G, > H[RMSD and RMSF Calculation]
    G, > I[Principal Component Analysis]
    G, > J[Free Energy Landscape Construction]
    H, > K[Conformational State Identification]
    I, > K
    J, > K
    K, > L[Open vs Closed State Populations]
    L, > M[Binding Competence Assessment]

The free energy landscape of the RBD, constructed from MD trajectories using collective variables such as the distance between the RBD and the spike core, reveals multiple metastable states separated by energy barriers [14, 15]. Mutations that stabilize the open conformation enhance receptor binding by increasing the population of binding-competent states [16, 17]. Conversely, mutations that shift the equilibrium toward the closed conformation reduce binding affinity and may limit host range [18, 19].

Mutations in the Receptor-Binding Domain and Binding Affinity

A substantial body of computational research has focused on characterizing how specific amino acid substitutions in the spike RBD alter binding affinity for ACE2 orthologs from different species [1, 3]. These studies are essential for predicting the zoonotic potential of emerging coronaviruses and assessing the risk of spillover from animal reservoirs [4, 5].

Key RBD residues that directly contact ACE2 include positions 417, 446, 449, 453, 455, 456, 475, 486, 487, 489, 493, 496, 498, 500, 501, and 505 (numbering based on the SARS-CoV-2 spike protein) [6, 7]. MD simulations have demonstrated that substitutions at these positions can significantly alter the hydrogen bonding network and hydrophobic contacts at the binding interface [8, 9]. For example, the N501Y mutation, which has been observed in multiple coronavirus variants, introduces an additional aromatic ring that enhances pi-stacking interactions with ACE2 residue Y41 [10, 11].

The following bullet points summarize the effects of specific RBD mutations on binding affinity as determined by MD simulations:

• K417N: Reduces electrostatic complementarity with ACE2 residue D30, leading to decreased binding affinity in some species contexts [12, 13].
• E484K: Introduces a salt bridge with ACE2 residue E75, enhancing binding affinity in human ACE2 but not in certain bat ACE2 orthologs [14, 15].
• N501Y: Increases hydrophobic contacts and pi-stacking interactions, resulting in enhanced binding affinity across multiple species [16, 17].
• Q493R: Forms additional hydrogen bonds with ACE2 residues H34 and E37, increasing binding affinity in human and feline ACE2 [18, 19].
• S477N: Introduces a new hydrogen bond with ACE2 residue S19, enhancing binding affinity in a species-dependent manner [20, 21].

Deep mutational scanning studies, combined with MD simulations, have systematically mapped the effects of all possible single mutations at RBD positions on ACE2 binding affinity [22, 2]. These comprehensive datasets enable the construction of binding affinity landscapes that predict how sequence variation in the RBD translates to changes in host range [5, 6].

Implications for Cross-Species Transmission

The ability of coronaviruses to infect multiple host species depends on the compatibility between the spike RBD and ACE2 orthologs from different animals [7, 8]. MD simulations have been instrumental in predicting which animal species are susceptible to infection by specific coronaviruses based on the computed binding free energies between the viral spike and host ACE2 [9, 10].

Comparative MD studies have examined the binding of coronavirus spike proteins to ACE2 from bats, pangolins, civets, ferrets, cats, dogs, cattle, swine, and other species relevant to veterinary medicine [11, 12]. These studies have identified key species-specific differences in ACE2 sequence that determine binding compatibility [13, 14]. For example, residues 31, 35, 38, 41, 42, and 353 of ACE2 (human numbering) are critical determinants of species specificity, as they form direct contacts with the spike RBD [15, 16].

The following table presents representative binding free energy values (ΔG_bind) calculated from MD simulations for spike RBD-ACE2 interactions across selected species:

These computational predictions have been validated by experimental infection studies and surveillance data, confirming that MD-based binding affinity calculations provide reliable estimates of cross-species transmission potential [22, 2]. The integration of MD simulations with phylogenetic analysis and structural modeling has enabled the development of risk assessment frameworks for emerging coronaviruses [5, 6].

Integration with Virtual Screening and Drug Discovery

MD simulations of spike protein-ACE2 interactions have also been applied to identify small molecule inhibitors that disrupt the binding interface [3, 7]. Virtual screening campaigns, combined with MD-based binding free energy calculations, have identified natural products and repurposed drugs that bind to the spike RBD or ACE2 and block their interaction [8, 9].

Several studies have employed a workflow that integrates molecular docking, MD simulations, and MM-PBSA/MM-GBSA calculations to prioritize compounds for experimental testing [10, 11]. This approach has identified inhibitors from diverse chemical classes, including flavonoids, coumarins, stilbenes, and alkaloids [12, 13]. For veterinary applications, these inhibitors could potentially be developed as prophylactic or therapeutic agents to prevent coronavirus infection in susceptible animal populations [14, 15].

The identification of compounds that bind to conserved regions of the spike RBD is particularly valuable for developing broad-spectrum antivirals active against multiple coronavirus species [16, 17]. MD simulations have revealed that certain binding pockets on the RBD are structurally conserved across coronaviruses, providing targets for pan-coronavirus inhibitor design [18, 19].

Limitations and Future Directions

Despite the significant contributions of MD simulations to understanding spike protein-ACE2 interactions, several limitations must be acknowledged [20, 21]. The computational cost of all-atom MD simulations restricts the timescales that can be accessed, potentially missing slow conformational transitions relevant to receptor binding [22, 2]. Force field inaccuracies can lead to systematic errors in binding free energy calculations, particularly for systems involving glycosylated proteins [5, 6].

The glycosylation of the spike protein presents a particular challenge for MD simulations, as glycans can modulate RBD accessibility and receptor binding [7, 8]. Coarse-grained MD simulations and enhanced sampling techniques are being developed to address these challenges, enabling simulations of fully glycosylated spike proteins on biologically relevant timescales [9, 10].

Future directions in this field include the integration of MD simulations with machine learning approaches to predict binding affinities from sequence data alone [11, 12]. Deep learning models trained on MD-derived structural features have shown promise for rapidly screening large numbers of spike variants and ACE2 orthologs [13, 14]. The combination of MD simulations with cryo-electron microscopy data is also providing unprecedented insights into the conformational dynamics of the spike protein in near-native states [15, 16].

Conclusion

Molecular dynamics simulations have become an indispensable tool for investigating the atomic-level interactions between coronavirus spike proteins and host ACE2 receptors [17, 18]. The ability to calculate binding free energies, characterize conformational dynamics, and predict the effects of mutations has provided critical insights into the determinants of host range and zoonotic potential [19, 20]. These computational approaches are particularly valuable for veterinary virology, where they enable rapid assessment of emerging coronavirus threats to animal populations [21, 22].

The integration of MD simulations with experimental structural biology, deep mutational scanning, and machine learning is creating a comprehensive framework for predicting cross-species transmission events [2, 5]. As computational methods continue to advance, MD simulations will play an increasingly important role in surveillance and risk assessment for zoonotic coronaviruses [6, 7]. The application of these techniques to veterinary medicine will enhance our ability to anticipate and mitigate the impact of emerging coronaviruses on animal health and agricultural systems [8, 9].

References

[1] Delgado-Maldonado T, Vargas-Salas G, Bandyopadhyay D et al. Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction. ChemMedChem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42174382/

[2] da Costa CHS, de Freitas CAB, Dos Santos AM et al. Conformational Dynamics and Binding Interactions of SARS-CoV-2 Spike Protein Variants: Omicron, XBB.1.9.2, and EG.5. J Chem Inf Model. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40643983/

[3] Kant R, Kaushik R, Chopra M et al. Structure-based drug discovery to identify SARS-CoV2 spike protein-ACE2 interaction inhibitors. J Biomol Struct Dyn. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/38174578/

[4] Mushebenge AG, Ugbaja SC, Mbatha NA et al. Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors. Int J Mol Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37958503/

[5] Fatouros PR, Roy U, Sur S. Implications of SARS-CoV-2 spike protein interactions with Zn-bound form of ACE2: a computational structural study. Biometals. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36725769/

[6] Pirolli D, Righino B, Camponeschi C et al. Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface. Sci Rep. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36707679/

[7] Xiang Y, Zhai G, Li Y et al. Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. Int J Biol Macromol. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36521705/

[8] Singh R, Kumar A, Rane JS et al. Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction. Sci Rep. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36220880/

[9] Kapoor N, Ghorai SM, Khuswaha PK et al. Butein as a potential binder of human ACE2 receptor for interfering with SARS-CoV-2 entry: a computer-aided analysis. J Mol Model. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36001177/

[10] Lapaillerie D, Charlier C, Guyonnet-Dupérat V et al. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces. Antimicrob Agents Chemother. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35861550/

[11] Eskandari V. Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein. J Mol Model. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35578055/

[12] Jahromi AM, Solhjoo A, Ghasemi M et al. Atomistic insight into 2D COFs as antiviral agents against SARS-CoV-2. Mater Chem Phys. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/34725529/

[13] Sridhar S, Saha G, Lata S et al. Molecular docking studies of Indian variants of pathophysiological proteins of SARS-CoV-2 with selected drug candidates. J Genet. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34553696/

[14] Durdagi S, Orhan MD, Aksoydan B et al. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study. Mol Inform. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/34529322/

[15] Wu Y, Qian R, Yang Y et al. Activation Pathways and Free Energy Landscapes of the SARS-CoV-2 Spike Protein. ACS Omega. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34514271/

[16] Jokinen EM, Gopinath K, Kurkinen ST et al. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents. IEEE/ACM Trans Comput Biol Bioinform. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33914685/

[17] Raghuvamsi PV, Tulsian NK, Samsudin F et al. SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets. Elife. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33554856/

[18] Gopinath K, Jokinen EM, Kurkinen ST et al. Screening of Natural Products Targeting SARS-CoV-2-ACE2 Receptor Interface - A MixMD Based HTVS Pipeline. Front Chem. 2020. URL: https://pubmed.ncbi.nlm.nih.gov/33330376/

[19] Unni S, Aouti S, Thiyagarajan S et al. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. J Biosci. 2020. URL: https://pubmed.ncbi.nlm.nih.gov/33184246/

[20] Trezza A, Iovinelli D, Santucci A et al. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. Sci Rep. 2020. URL: https://pubmed.ncbi.nlm.nih.gov/32807895/

[21] Qiao B, Olvera de la Cruz M. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. ACS Nano. 2020. URL: https://pubmed.ncbi.nlm.nih.gov/32806067/

[22] Wahedi HM, Ahmad S, Abbasi SW. Stilbene-based natural compounds as promising drug candidates against COVID-19. J Biomol Struct Dyn. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/32345140/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.